Viridian Therapeutics Stock Target Price and Analyst Consensus
| VRDN Stock | USD 19.43 0.22 1.15% |
The current analyst and expert consensus on Viridian Therapeutics is Strong Buy, with 10 strong buy opinions. The current projected Viridian Therapeutics target price consensus is 40.44 with 17 analyst opinions. Check out Macroaxis Advice on Viridian Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.The most common way Viridian Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Viridian Therapeutics executives and customers to further validate their buy or sell advice. Viridian Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected Viridian Therapeutics target price to derive its highest and lowest estimates based on projected price volatility of 4.479.
Lowest Forecast 36.8 | Highest Forecast 44.89 | Target Price 40.44 |
Viridian |
It's important to approach Viridian Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Viridian Therapeutics Target Price Consensus
Viridian target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Viridian Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 17 | Strong Buy |
Most Viridian analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Viridian stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Viridian Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationViridian Therapeutics Target Price Projection
Viridian Therapeutics' current and average target prices are 19.43 and 40.44, respectively. The current price of Viridian Therapeutics is the price at which Viridian Therapeutics is currently trading. On the other hand, Viridian Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Viridian Therapeutics Market Quote on 30th of January 2025
Target Price
Analyst Consensus On Viridian Therapeutics Target Price
Viridian Therapeutics Analyst Ratings
Viridian Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Viridian Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Viridian Therapeutics' financials, market performance, and future outlook by experienced professionals. Viridian Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Viridian Therapeutics price targets
Viridian Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Viridian Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Viridian Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Viridian Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Viridian Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Viridian Therapeutics is a key component of Viridian Therapeutics valuation and have some predictive power on the future returns of a Viridian Therapeutics.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Viridian Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Momentum Invested over 300 shares | |
 | Dividend Beast Invested over 50 shares | |
 | Hedge Favorites Invested over 100 shares | |
 | Driverless Cars Invested few shares | |
 | Banking Invested over 30 shares | |
 | Warren Buffett Holdings Invested over 60 shares | |
 | Business Services Invested few shares | |
 | Automobiles and Trucks Invested over 300 shares | |
 | FinTech Invested over 60 shares | |
 | Investor Favorites Invested over 300 shares | |
 | Chemicals Invested over 30 shares | |
 | Artificial Intelligence Invested few shares |
Check out Macroaxis Advice on Viridian Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.